Influencer Addresses GLP-1 Stomach Paralysis Speculation
- A 31-year-old social media influencer from Oklahoma City is publicly addressing widespread speculation that her diagnosed stomach paralysis resulted from using GLP-1 weight loss medications, stating she has...
- Shayla Talei, who has built a following of 249,000 on TikTok by documenting her life with chronic illnesses, clarified in an exclusive interview with People.com published on Thursday,...
- … There’s just so many ways that you can get it, and it’s nothing that I did to myself.”
A 31-year-old social media influencer from Oklahoma City is publicly addressing widespread speculation that her diagnosed stomach paralysis resulted from using GLP-1 weight loss medications, stating she has never taken such drugs and attributes her significant weight loss solely to her medical condition.
Shayla Talei, who has built a following of 249,000 on TikTok by documenting her life with chronic illnesses, clarified in an exclusive interview with People.com published on Thursday, April 16, 2026, that her gastroparesis diagnosis — often referred to as stomach paralysis — is not connected to any use of glucagon-like peptide-1 receptor agonist drugs.
“I’ve never been on one,” Talei told People. “I just lost a lot of weight because of the condition. … There’s just so many ways that you can get it, and it’s nothing that I did to myself.”
Her comments come amid growing public discussion online about the potential gastrointestinal side effects of GLP-1 medications, which have surged in popularity for weight management. A May 2024 study published by the Cleveland Clinic noted an increased risk of gastroparesis associated with these drugs, fueling speculation in comment sections beneath her social media posts about whether her condition stemmed from medication use.
Medical Background and Diagnosis
Talei lives with two chronic conditions: complex regional pain syndrome (CRPS), which she was diagnosed with at age 17, and gastroparesis, which was officially identified just two years ago. CRPS is a chronic pain disorder characterized by pain disproportionate to the initial injury, often developing after trauma, surgery, stroke, or heart attack, according to the Mayo Clinic.
Gastroparesis, as defined by the Mayo Clinic, is a condition that impairs the stomach muscles’ ability to move food properly through the digestive tract, effectively paralyzing the stomach’s natural motility. This disruption prevents normal digestion and can lead to severe symptoms after eating.
Symptoms and Impact on Daily Life
Before her diagnosis, Talei experienced debilitating symptoms that made eating extremely painful and difficult. Consuming food triggered intense bloating, nausea, and vomiting, while even drinking water felt physically agonizing.
“Water, she says, ‘feels like glass shards’ in her stomach,” according to her account shared with media outlets. At the height of her symptoms, she was sometimes able to tolerate only three bites of food over the course of an entire day.
Weight Loss and Medical Investigation
The persistent inability to eat without severe discomfort led to substantial, unintentional weight loss. Over an eight-month period prior to her official diagnosis, Talei lost approximately 100 pounds as her body struggled to process nutrition.
This dramatic change occurred while doctors were still investigating the underlying cause of her symptoms. The weight loss was not the result of intentional dieting or medication use but a direct consequence of her body’s inability to tolerate food due to gastroparesis.
Public Advocacy and Social Media Presence
Despite the challenges posed by her conditions, Talei has used her platform to share her daily routine with hundreds of thousands of followers, aiming to foster understanding and reduce stigma around invisible illnesses. She regularly posts about managing her health, including how she navigates eating with a paralyzed stomach.
Her content focuses on the realities of living with chronic illness, from medical routines to adaptive strategies for daily living. By sharing her experiences openly, she has created a space where others with similar conditions can feel seen and supported.
Medical Context on GLP-1 and Gastroparesis
While Talei emphasizes her personal history does not include GLP-1 use, medical research has identified a potential association between these medications and gastrointestinal motility issues. The Cleveland Clinic study from May 2024, which she referenced, found an increased risk of gastroparesis among users of GLP-1 receptor agonists.
However, medical experts note that gastroparesis can arise from various causes, including diabetes, neurological disorders, viral infections, and idiopathic origins — meaning the cause is unknown. In Talei’s case, her gastroparesis developed approximately ten years after her CRPS diagnosis, suggesting a complex interplay of chronic conditions rather than a single triggering factor.
Healthcare providers caution against assuming causation from correlation, especially in cases involving popular medications where anecdotal reports may not reflect broader epidemiological data. Accurate diagnosis requires comprehensive medical evaluation, including gastric emptying studies and exclusion of other potential causes.
As conversations about weight loss medications and their side effects continue to evolve, Talei’s public clarification serves as a reminder that conditions like gastroparesis have multiple potential origins and should not be assumed to stem from any single factor without medical confirmation.
A 31-year-old social media influencer from Oklahoma City is publicly addressing widespread speculation that her diagnosed stomach paralysis resulted from using GLP-1 weight loss medications, stating she has never taken such drugs and attributes her significant weight loss solely to her medical condition.
Shayla Talei, who has built a following of 249,000 on TikTok by documenting her life with chronic illnesses, clarified in an exclusive interview with People.com published on Thursday, April 16, 2026, that her gastroparesis diagnosis — often referred to as stomach paralysis — is not connected to any use of glucagon-like peptide-1 receptor agonist drugs.
“I’ve never been on one,” Talei told People. “I just lost a lot of weight because of the condition. … There’s just so many ways that you can get it, and it’s nothing that I did to myself.”
Her comments come amid growing public discussion online about the potential gastrointestinal side effects of GLP-1 medications, which have surged in popularity for weight management. A May 2024 study published by the Cleveland Clinic noted an increased risk of gastroparesis associated with these drugs, fueling speculation in comment sections beneath her social media posts about whether her condition stemmed from medication use.
Medical Background and Diagnosis
Talei lives with two chronic conditions: complex regional pain syndrome (CRPS), which she was diagnosed with at age 17, and gastroparesis, which was officially identified just two years ago. CRPS is a chronic pain disorder characterized by pain disproportionate to the initial injury, often developing after trauma, surgery, stroke, or heart attack, according to the Mayo Clinic.
Gastroparesis, as defined by the Mayo Clinic, is a condition that impairs the stomach muscles’ ability to move food properly through the digestive tract, effectively paralyzing the stomach’s natural motility. This disruption prevents normal digestion and can lead to severe symptoms after eating.
Symptoms and Impact on Daily Life
Before her diagnosis, Talei experienced debilitating symptoms that made eating extremely painful and difficult. Consuming food triggered intense bloating, nausea, and vomiting, while even drinking water felt physically agonizing.
“Water, she says, ‘feels like glass shards’ in her stomach,” according to her account shared with media outlets. At the height of her symptoms, she was sometimes able to tolerate only three bites of food over the course of an entire day.
Weight Loss and Medical Investigation
The persistent inability to eat without severe discomfort led to substantial, unintentional weight loss. Over an eight-month period prior to her official diagnosis, Talei lost approximately 100 pounds as her body struggled to process nutrition.
This dramatic change occurred while doctors were still investigating the underlying cause of her symptoms. The weight loss was not the result of intentional dieting or medication use but a direct consequence of her body’s inability to tolerate food due to gastroparesis.
Public Advocacy and Social Media Presence
Despite the challenges posed by her conditions, Talei has used her platform to share her daily routine with hundreds of thousands of followers, aiming to foster understanding and reduce stigma around invisible illnesses. She regularly posts about managing her health, including how she navigates eating with a paralyzed stomach.
Her content focuses on the realities of living with chronic illness, from medical routines to adaptive strategies for daily living. By sharing her experiences openly, she has created a space where others with similar conditions can feel seen and supported.
Medical Context on GLP-1 and Gastroparesis
While Talei emphasizes her personal history does not include GLP-1 use, medical research has identified a potential association between these medications and gastrointestinal motility issues. The Cleveland Clinic study from May 2024, which she referenced, found an increased risk of gastroparesis among users of GLP-1 receptor agonists.
However, medical experts note that gastroparesis can arise from various causes, including diabetes, neurological disorders, viral infections, and idiopathic origins — meaning the cause is unknown. In Talei’s case, her gastroparesis developed approximately ten years after her CRPS diagnosis, suggesting a complex interplay of chronic conditions rather than a single triggering factor.
Healthcare providers caution against assuming causation from correlation, especially in cases involving popular medications where anecdotal reports may not reflect broader epidemiological data. Accurate diagnosis requires comprehensive medical evaluation, including gastric emptying studies and exclusion of other potential causes.
As conversations about weight loss medications and their side effects continue to evolve, Talei’s public clarification serves as a reminder that conditions like gastroparesis have multiple potential origins and should not be assumed to stem from any single factor without medical confirmation.